Jointly provided by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC.
Dinner is provided by Impact Education, LLC.
|
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
|
The program will feature a multidisciplinary panel including an EoE clinical specialist and Northwest Region managed care/payer experts.
|
|
Who Should Attend?
|
This activity is designed to meet the educational needs of AMCP Northwest affiliate members in the roles of pharmacy directors, clinical pharmacists, specialty pharmacists, medical directors, registered nurses, quality directors, and other pharmacists and physicians affiliated with various MCOs, health systems, and other payer organizations.
The CE is clinically focused, and Impact Education is hoping to get feedback and engagement from those at health plans and PBMs on how the disease is presenting in the region and how payers are navigating the treatment landscape.
Participate in the pre-program survey: Click Here
The password to enter is: eoe
|
|
Statement of Need/Program Overview
|
EoE is difficult to diagnose and treat, and as a result is associated with a high disease burden. Once payer decision makers recognize the disease has consequences and associated costs, they are interested in streamlining and standardizing its management to improve access to appropriate care. Managed care and payer professionals are well positioned to design and implement policies that have a considerable influence on patient access to appropriate care of EoE. Based on findings from previous initiatives, disease state baseline knowledge and awareness still needs to be improved and payers continue to need additional education to apply regional health plan best practices to improve EoE management. Incorporating an understanding of regional variances in EoE into healthcare strategies can ultimately lead to better outcomes for individuals with this condition while optimizing the utilization of healthcare resources and managing costs.
|
|
Educational Objectives
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Discuss the diagnostic journey of patients with EoE and the importance of early diagnosis
- Assess evidence-based treatment strategies and resources for optimal patient outcomes in EoE
- Employ regional benefit design strategies that facilitate appropriate patient access to evidence-based treatment options for EoE
- Implement collaborative regional payer/provider initiatives to improve the treatment of EoE
|
|
Agenda
|
Date and Time
Thursday, February 29, 2024
5:30 PM - 6:30 PM PT - Registration and Reception
6:30 PM - 8:00 PM PT - Dinner and Presentation
Daniel's Broiler
NE 8th St.
21st Floor
Bellevue, WA 98004
Dinner and drinks provided by Impact Education, LLC.
|
Evidence-Based Diagnosis and Treatment of EoE
- Patient journey to diagnosis
- Disease overview
- Treatment goals and key considerations
|
Improving Access to Timely Treatments
- Access barriers to treatment options
- Patient case presentation
|
Moderated Northwest Region Panel Discussion
- Understanding regional perspectives on EoE
- Regional opportunities to improve the quality of care
- Collaborative opportunities and health plan best practices
|
|
Accreditation Information
|
|
Joint Accreditation Statement |
 |
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Physician Continuing Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: JA4008073-9999-24-008-L01-P
Type of Activity: Application
|
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
|
Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Fee Information
There is no fee for this educational activity.
|
|
